Page 1872 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

Chapter 126

REFERENCES

1. Janssen NM, Karnad DR, Guntupalli KK. Rheumatologic 14. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am.
diseases in the intensive care unit: epidemiology, clinical May 2003;29(2):315-333.
approach, management, and outcome. Crit Care Clin. October 15. Guillevin L, Berezne A, Seror R, et al. Scleroderma renal crisis: a
2002;18(4):729-748. retrospective multicentre study on 91 patients and 427 controls.
2. Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythe- Rheumatology (Oxford). 2012;51(3):460-467.
matosus: clinical and immunologic patterns of disease expres- 16. Hesselstrand R, Scheja A, Wuttge D. Scleroderma renal crisis
sion in a cohort of 1,000 patients. The European Working Party in a Swedish systemic sclerosis cohort: survival, renal outcome,
on Systemic Lupus Erythematosus. Medicine (Baltimore). March and RNA polymerase III antibodies as a risk factor. Scand J
1993;72(2):113-124. Rheumatol. February 2012;41(1):39-43.
3. Inoue T, Takeda T, Koda S, et al. Differential diagnosis of fever 17. Rhew EY, Barr WG. Scleroderma renal crisis: new insights and
in systemic lupus erythematosus using discriminant analysis. developments. Curr Rheumatol Rep. April 2004;6(2):129-136.
Rheumatol Int. 1986;6(2):69-77.
4. Iliopoulos AG, Tsokos GC. Immunopathogenesis and spectrum 18. Dhaun N, MacIntyre IM, Bellamy CO, Kluth DC. Endothelin
receptor antagonism and renin inhibition as treatment
of infections in systemic lupus erythematosus. Semin Arthritis options for scleroderma kidney. Am J Kidney Dis. October
Rheum. April 1996;25(5):318-336. 2009;54(4):726-731.
5. Boumpas DT, Austin HA III, Fessler BJ, Balow JE, Klippel 19. Marinelli WA, Leatherman JW. Neuromuscular disorders in
JH, Lockshin MD. Systemic lupus erythematosus: emerging the intensive care unit. Crit Care Clin. October 2002;18(4):
concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pul- 915-929, x.
monary, and hematologic disease. Ann Intern Med. June 15,
1995;122(12):940-950. 20. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis.
Lancet. September 20, 2003;362(9388):971-982.
6. Ponticelli C, Moroni G. Renal transplantation in lupus nephri-
tis. Lupus. 2005;14(1):95-98. 21. Edwards RH, Round JM, Jones DA. Needle biopsy of skel-
7. Kamen DL, Strange C. Pulmonary manifestations of sys- etal muscle: a review of 10 years experience. Muscle Nerve.
temic lupus erythematosus. Clin Chest Med. September November-December 1983;6(9):676-683.
2010;31(3):479-488. 22. Fathi M, Lundberg IE, Tornling G. Pulmonary complications of
polymyositis and dermatomyositis. Semin Respir Crit Care Med.
8. Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and man-
agement of neuropsychiatric SLE manifestations. Nat Rev August 2007;28(4):451-458.
Rheumatol. June 2010;6(6):358-367. 23. Aggarwal R, Oddis CV. Therapeutic approaches in myositis.
9. Widener HL, Littman BH. Ibuprofen-induced meningitis in Curr Rheumatol Rep. June 2011;13(3):182-191.
systemic lupus erythematosus. Jama. March 13, 1978;239(11): 24. Saravanan V, Kelly CA. Reducing the risk of methotrexate
1062-1064. pneumonitis in rheumatoid arthritis. Rheumatology (Oxford).
10. Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ. Transverse February 2004;43(2):143-147.
myelopathy in systemic lupus erythematosus: an analysis of 25. Neva MH, Kauppi MJ, Kautiainen H, et al. Combination drug
14 cases and review of the literature. Ann Rheum Dis. February therapy retards the development of rheumatoid atlantoaxial sub-
2000;59(2):120-124. luxations. Arthritis Rheum. November 2000;43(11):2397-2401.
11. Kur JK, Esdaile JM. Posterior reversible encephalopathy 26. Goldbach-Mansky R. Blocking interleukin-1 in rheumatic dis-
syndrome—an underrecognized manifestation of systemic lupus eases. Ann N Y Acad Sci. December 2009;1182:111-123.
erythematosus. J Rheumatol. November 2006;33(11):2178-2183. 27. Goldbach-Mansky R, Kastner DL. Autoinflammation: the
12. George JN. Clinical practice. Thrombotic thrombocytopenic prominent role of IL-1 in monogenic autoinflammatory dis-
purpura. N Engl J Med. May 4, 2006;354(18):1927-1935. eases and implications for common illnesses. J Allergy Clin
13. Hant FN, Herpel LB, Silver RM. Pulmonary manifestations of Immunol. December 2009;124(6):1141-1149; quiz 1141-1151.
scleroderma and mixed connective tissue disease. Clin Chest 28. Godeau B, Mortier E, Roy PM, et al. Short and longterm out-
Med. September 2010;31(3):433-449. comes for patients with systemic rheumatic diseases admitted

Section11-O-Ref.indd 1 12/10/2014 8:08:27 PM